Drug Landscape ›
Japanese Encephalitis Vaccine ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Aspartate Aminotransferase Increased — 1 report (10%) Bronchitis — 1 report (10%) Cardiac Arrest — 1 report (10%) Death — 1 report (10%) Depressed Level Of Consciousness — 1 report (10%) Dizziness — 1 report (10%) Drug Interaction — 1 report (10%) Dysgraphia — 1 report (10%) Encephalopathy — 1 report (10%) Fall — 1 report (10%)
Source database →
Japanese Encephalitis Vaccine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Japanese Encephalitis Vaccine approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Japanese Encephalitis Vaccine in United States?
Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.